Spectral MD went public via a SPAC merger with Rosecliff Acquisition I in a $170m deal.

Spectral MD, an Artificial Intelligence company focused on predictive medical diagnostics, went public via a SPAC merger with Rosecliff Acquisition I, a special purpose acquisition company listed on Nasdaq, in a $170m deal. “This transaction is an excellent strategic move for Spectral MD. For the past 10 years, the Spectral MD team and our key partners have been developing cutting edge AI solutions that have demonstrated tremendous promise and are now on the cusp of delivering for healthcare providers and patients. Spectral MD solves an unmet need in healthcare that goes far beyond current solutions by leveraging relevant AI technology to enhance the diagnostic accuracy of the healthcare provider, improve patient outcomes and significantly lower costs. The Nasdaq listing will ensure we are well positioned to capitalize on U.S. federal procurement contracts, our planned FDA and CE mark submissions in 2023 and 2024, and our commercialization roadmap for burn, DFU, 3-D wound size measurement, as well as support the advancement of additional pipeline clinical applications. I am excited to be working with the Rosecliff team in executing our vision of transforming patient care and improving clinical outcomes,” Wensheng Fan, Spectral MD CEO.